Aminoindan derivatives

Details Aminoindan derivatives Aminoindan derivatives

2001-08-31

2003-03-25

Barts, Samuel (Department: 1621)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

N-c doai

C514S481000

Reexamination Certificate

active

06538025

ABSTRACT:

FIELD OF INVENTION
The present invention relates to novel compounds, pharmaceutical compositions containing said compounds and their use in the treatment of various CNS disorders.
BACKGROUND OF THE INVENTION
Dementia exists in several forms including static dementia, Alzheimer's-type dementia, senile dementia, presenile dementia and progressive dementia. One of the common pathological features of several types of dementia is the lack of the neurotransmitter acetylcholine. This has led to the development of acetylcholine esterase inhibitors for use in the treatment of dementias such as the compound tacrine. A summary of the different approaches to and progress made in the treatment of Alzheimer's Disease may be found in Drugs of the Future (1995) 20(11): 1145-1162.
Recently, compounds that in addition to inhibiting acetylcholine esterase, possess inhibitory activity against monoamine oxidase type A (MAO-A) have been developed. The perceived benefit of having the anti-MAO-A activity is stated to be an anti-depressant effect (European Patent Publication Nos. 614,888 and 664,291).
U.S. Pat. Nos. 5,387,133, 5,453,446, 5,457,133 and 5,519,061 all disclose that the compound (R)-N-propargyl-1-aminoindan, a highly selective monoamine oxidase type B (MAO-B) inhibitor is effective in the treatment of dementias of the Alzheimer type and memory disorders. There is no indication given therein that the compound might have acetylcholine esterase inhibitory activity. Furthermore, the compound is only very weakly active as a MAO-A inhibitor.
PCT International Publication No. WO95/18617 discloses various aminoindan derivatives that are active in a variety of CNS disorders including dementias of the Alzheimer type. There is no indication given therein that any of the compounds disclosed might have acetylcholine esterase inhibitory activity.
SUMMARY OF THE INVENTION
The present invention relates to compounds of formula I
wherein when a is 0; b is 1 or 2; when a is 1, b is 1; m is from 0 to 3; X is C or S; Y is halogeno; R
1
is hydrogen or C
1-4
alkyl; R
2
is hydrogen, C
1-4
alkyl or optionally substituted propargyl; and R
3
and R
4
are each independently hydrogen, C
1-8
alkyl, C
6-12
aryl, C
6-12
aralkyl or C
6-12
cycloalkyl optionally substituted.
The invention relates to the compounds themselves, pharmaceutical compositions containing said compounds and their use in the treatment of depression, Attention Deficit Disorder (ADD), Attention Deficit and Hyperactivity Disorder (ADHD), Tourette's Syndrome, Alzheimer's Disease and other dementias such as senile dementia, presenile dementia, progressive dementia, dementia of the Parkinson's type, vascular dementia and Lewy body dementia.
A further aspect of the present invention relates to the use of the compounds of formula I in the treatment of neurotraumatic disorder. As used herein the term “neurotraumatic disorder” is meant to include damage caused to the nervous system (both central and peripheral) by virtue of ischemic damage such as that which occurs in stroke, hypoxia or anoxia, neurodegenerative diseases, Parkinson's Disease, Alzheimer's Disease, Huntington's Disease, neurotoxic injury, head trauma injury, spinal trauma injury, peripheral neuropathy or any form of nerve damage.
An additional aspect of the present invention relates to the use of the compounds of formula I in the treatment of memory disorder or depression.
The present invention relates to the racemic compounds themselves and optically active enantiomers thereof.


REFERENCES:
patent: 2573645 (1951-10-01), Kerwin et al.
patent: 2916490 (1959-12-01), Schenck et al.
patent: 2982783 (1961-05-01), Schenck et al.
patent: 3060091 (1962-10-01), Witkin
patent: 3123642 (1964-03-01), Temple et al.
patent: 3178478 (1965-04-01), Huebner et al.
patent: 3201470 (1965-08-01), Huebner et al.
patent: 3253037 (1966-05-01), Huebner et al.
patent: 3308157 (1967-03-01), Robertson et al.
patent: 3507962 (1970-04-01), Taylor
patent: 3513240 (1970-05-01), Bernadus et al.
patent: 3513244 (1970-05-01), Gittos et al.
patent: 3637740 (1972-01-01), Sarges
patent: 3704323 (1972-11-01), Krapcho
patent: 3709996 (1973-01-01), Gittos et al.
patent: 3751420 (1973-08-01), Hauck et al.
patent: 3804898 (1974-04-01), Panneman
patent: 3886168 (1975-05-01), Himmele et al.
patent: 3991207 (1976-11-01), Sarges et al.
patent: 4029731 (1977-06-01), Sarges
patent: 4096173 (1978-06-01), Molloy
patent: 4128666 (1978-12-01), Bondinell et al.
patent: 4132737 (1979-01-01), Molloy
patent: 4134997 (1979-01-01), Cannon et al.
patent: 4172093 (1979-10-01), Göransson-Dahlander et al.
patent: 4632939 (1986-12-01), Beedle et al.
patent: 4638001 (1987-01-01), Kuhla et al.
patent: 4788130 (1988-11-01), Oshiro et al.
patent: 4792628 (1988-12-01), Oshiro et al.
patent: 4826875 (1989-05-01), Chiesi
patent: 4833273 (1989-05-01), Goel et al.
patent: 4873241 (1989-10-01), Napier et al.
patent: 4948807 (1990-08-01), Rosin et al.
patent: 5011995 (1991-04-01), Pugin et al.
patent: 5071875 (1991-12-01), Horn et al.
patent: 5118704 (1992-06-01), Minaskanian et al.
patent: 5134147 (1992-07-01), Peglion et al.
patent: 5153225 (1992-10-01), Schohe et al.
patent: 5189045 (1993-02-01), Peglion et al.
patent: 5196583 (1993-03-01), Yamada et al.
patent: 5225596 (1993-07-01), Carlsson et al.
patent: 5242919 (1993-09-01), Oshiro et al.
patent: 5273974 (1993-12-01), Goto et al.
patent: 5286747 (1994-02-01), Arvidsson et al.
patent: 5378729 (1995-01-01), Kohn et al.
patent: 5387612 (1995-02-01), Youdim et al.
patent: 5389687 (1995-02-01), Schaus et al.
patent: 5401758 (1995-03-01), Atwal et al.
patent: 5453446 (1995-09-01), Youdim et al.
patent: 5457133 (1995-10-01), Youdim et al.
patent: 5516943 (1996-05-01), Gao et al.
patent: 5519061 (1996-05-01), Youdim et al.
patent: 5532415 (1996-07-01), Youdim et al.
patent: 5569669 (1996-10-01), Guillaumet et al.
patent: 5602176 (1997-02-01), Enz
patent: 5646188 (1997-07-01), Gilad et al.
patent: 5654301 (1997-08-01), Kohn et al.
patent: 5708018 (1998-01-01), Haadsma-Svensson et al.
patent: 5877218 (1999-03-01), Herzig et al.
patent: 5914349 (1999-06-01), Cohen et al.
patent: 6303650 (2001-10-01), Chorev et al.
patent: 0436492 (1991-10-01), None
patent: 664291 (1993-10-01), None
patent: 614888 (1994-02-01), None
patent: 0852735 (1960-11-01), None
patent: 1003686 (1965-09-01), None
patent: WO9100724 (1991-01-01), None
patent: WO9504027 (1995-02-01), None
patent: WO9511016 (1995-04-01), None
patent: WO9518617 (1995-07-01), None
patent: WO9602524 (1996-02-01), None
Armstrong et al., “Acylation Effects on Chiral Recognition of Racemic Amines and Alcohols by New Polar and Non-Polar Cyclodextrin Derivative Gas Chromatograhic Phases”,J. Chromatography(1990) 502: 154-159.
Askin et al., “Highly Diastereoselective Alkylations of Chiral Amide Enolates: New Routes to Hydroxyethylene Dipeptiede Isostere Inhibitors of HIV-1 Protease”,J. Org. Chem.(1992) 57(10): 2771-2773.
Baker et al., “Synthesis of Decahydrocyclopentacyclo-octene Derivatives via Intramolecular—Photocycloaddition of &Dgr;&agr;,&bgr;Butenolides and Reductive Cleavage”,J. Chem. Soc. Chem. Comm.(1980) 23: 1011-1012.
Barton et al., “Reductive Formylation of Oximes; An Approach to the Synthesis of Vinyl Isonitriles”,Tetrahedron Letters(1988) 29(27): 3343-3346.
Boar et al., “A Simple Synthesis of Enamides from Ketoximes”,J. Chem. Soc. Perkins I(1975) 1237-1241.
Brettle et al., “Synthesis of Enamides”,J. Chem. Soc. Perkin Trans. I, (1988) 2185-2193.
Burk et al., “A Three-Step Procedure for Asymmetric Catalytic Reductive Amidation of Ketones”,J. Org. Chem.(1998), 63, 6084-6085.
Chorvat et al., “Acetycholine Release Enhancing Agents: Potential Therapeutics For Alzheimer's Disease”,Drugs of the Future(1995) 20(11):1145-1162.
Cooper et al., “Alzheimer's Disease Drug Treatment”,J. Ger. Drug Ther., (1993) 8(2):5-18.
Cutler et al., “Muscarinic M1-Receptor Agonists”,CNS Drugs(1995) 3(6):467-481.
Davis et al., “Tacrine”,The Lancet(1995) 345:625-630.
Drefahl et al., “Amino Alcohols. I. Cis- and Trans-DL-1-amino-1-hyd

Affiliated with

Also associated with

Rating

Aminoindan derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Aminoindan derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aminoindan derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3071158